BOSTON SCIENTIFIC CORP (BSX)

US1011371077 - Common Stock

68.49  -0.13 (-0.19%)

After market: 68.12 -0.37 (-0.54%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

BOSTON SCIENTIFIC CORP

NYSE:BSX (3/28/2024, 8:04:01 PM)

After market: 68.12 -0.37 (-0.54%)

68.49

-0.13 (-0.19%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap100.48B
Shares
PE33.41
Fwd PE30.07
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

New York Stock Exchange, Inc. Stock Screener

Find more stocks on New York Stock Exchange, Inc.

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

BSX Daily chart

Company Profile

Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical procedures. The company is headquartered in Marlborough, Massachusetts and currently employs 45,000 full-time employees. The Company’s segments include MedSurg and Cardiovascular. The MedSurg segment includes Endoscopy and Urology and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal and pulmonary conditions. Its Urology and Neuromodulation business develops and manufactures devices to treat various urological, neurological movement disorders and pelvic conditions. Its Cardiac Rhythm Management develops and manufactures a variety of implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. The Cardiovascular segment include Interventional Cardiology and Peripheral Interventions. Its Interventional Cardiology develops and manufactures technologies for diagnosing and treating coronary artery disease and structural heart conditions. Its product offerings include 360 Clips and RESONATE, among others.

Company Info

BOSTON SCIENTIFIC CORP

300 Boston Scientific Way

Marlborough MASSACHUSETTS 01752

P: 15086834000

CEO: Michael F. Mahoney

Employees: 45000

Website: https://www.bostonscientific.com/en-US/Home.html

BSX News

News Image4 days ago - Scivita MedicalScivita Medical Expands Collaboration with Boston Scientific

/PRNewswire/ -- Recently, Scivita Medical Technology Co., Ltd. ("Scivita Medical") and Boston Scientific Corporation (NYSE: BSX), a leading global medical...

News Image4 days ago - Scivita MedicalScivita Medical Expands Collaboration with Boston Scientific

/CNW/ -- Recently, Scivita Medical Technology Co., Ltd. ("Scivita Medical") and Boston Scientific Corporation (NYSE: BSX), a leading global medical technology...

News Image14 days ago - Investor's Business DailyWhy Abbott's Formula-Related Sell-Off Could Be A Buying Opportunity, Says Analyst

Fellow infant formula maker Reckitt Benckiser was ordered to pay $60 million to a mother whose baby died after eating Enfamil.

News Image15 days ago - Market News VideoBSX November 15th Options Begin Trading
News Image18 days ago - Investor's Business DailyTandem Diabetes Care Stock Belongs On Your Watchlist As RS Rating Jump Higher

On Monday, Tandem Diabetes Care stock received an upgrade to its Relative Strength (RS) Rating, from 68 to 78.

News Image18 days ago - ChartmillNYSE:BSX may be ready to breakout.

Will BOSTON SCIENTIFIC CORP breakout?

BSX Twits

Here you can normally see the latest stock twits on BSX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example